Values First Advisors Inc. Has $484,000 Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Values First Advisors Inc. cut its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 8.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,906 shares of the specialty pharmaceutical company’s stock after selling 1,506 shares during the period. Values First Advisors Inc.’s holdings in Collegium Pharmaceutical were worth $484,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in COLL. Nisa Investment Advisors LLC boosted its holdings in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 316 shares in the last quarter. TD Private Client Wealth LLC lifted its holdings in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares in the last quarter. Foundry Partners LLC grew its position in Collegium Pharmaceutical by 3.3% in the 3rd quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 509 shares during the period. Caprock Group LLC grew its position in Collegium Pharmaceutical by 6.7% in the 4th quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company’s stock valued at $249,000 after purchasing an additional 543 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after purchasing an additional 642 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on COLL. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Friday, January 10th. Piper Sandler decreased their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. Finally, StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $43.60.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the sale, the executive vice president now directly owns 119,184 shares in the company, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.98% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Trading Down 3.3 %

Shares of COLL stock opened at $30.53 on Thursday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a market capitalization of $984.59 million, a price-to-earnings ratio of 13.16 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a 52-week low of $28.39 and a 52-week high of $42.29. The company has a 50-day simple moving average of $31.03 and a two-hundred day simple moving average of $34.01.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.